Illumina this week provided an update regarding the uptake of its recently launched Eco real-time benchtop PCR system; and bolstered its nucleic acid sample preparation and specialty enzyme business by acquiring Epicentre Biotechnologies.

In a presentation this week at the JP Morgan Global Healthcare Conference in San Francisco, Illumina President and CEO Jay Flatley told attendees that fourth-quarter 2010 orders for the Eco tripled and shipments nearly tripled compared to the third quarter of 2010, when Illumina launched the instrument.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.